Neurocrine Biosciences
NBIX
405 hedge funds and large institutions have $7.57B invested in Neurocrine Biosciences in 2021 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 141 increasing their positions, 141 reducing their positions, and 57 closing their positions.
26% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 57
3% more funds holding
Funds holding: 395 → 405 (+10)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 141 | Existing positions reduced: 141
1.37% less ownership
Funds ownership: 95.35% → 93.98% (-1.4%)
13% less capital invested
Capital invested by funds: $8.65B → $7.57B (-$1.08B)
14% less call options, than puts
Call options by funds: $44.6M | Put options by funds: $52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$116M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$46.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$40.2M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$38.5M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$37.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$257M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$142M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$86.3M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$58.5M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$46.2M |
NBIX Hedge Fund Activity: Q4 2021 in Review
405 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2021, worth a combined $7.57B — down 13% from $8.65B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new NBIX positions and 57 closed out — a net gain of 15 holders — while 141 added to existing stakes and 141 trimmed.
The largest buyer was BlackRock, adding an estimated $116M. The largest seller was Fidelity Investments, cutting an estimated $257M.
- 405 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2021, up from 395 in Q3 2021.
- Funds reported $7.57B of Neurocrine Biosciences stock for Q4 2021, down 13% quarter-over-quarter.
- 72 funds opened new Neurocrine Biosciences positions in Q4 2021 and 57 closed out, a net change of +15 holders.
- The largest Neurocrine Biosciences buyer in Q4 2021 was BlackRock, an estimated $116M added.
- The largest Neurocrine Biosciences seller in Q4 2021 was Fidelity Investments, an estimated $257M sold.
Based on aggregated 13F filings for Q4 2021.